# US 8,784,798 B2 · Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,798 B2
- Document ID: US8784798B2
- Status: Granted
- Kind: B2
- Application number: 13/319,649
- Filed: 2010-05-07
- Published: 2012-05-10
- Granted: 2014-07-22
- Earliest claimed: 2009-05-11
- Assignees: Nestec S.A.
- Applicants: Valerie Petit; Clara Garcia-Rodenas; Monique Julita; Guenolee Prioult; Annick Mercenier; Sophie Nutten
- Inventors: Valerie Petit; Clara Garcia-Rodenas; Monique Julita; Guenolee Prioult; Annick Mercenier; Sophie Nutten
- Web page: https://patentgrep.com/patent/US8784798B2

## CPC

- A61K 35/745: Bifidobacteria
- A23K 10/18: of live microorganisms
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/04: for throat disorders
- A61P 11/06: Antiasthmatics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/02: for disorders of the vagina
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 1/005: {after treatment of microbial biomass not covered by C12N1/02 - C12N1/08}
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/36: Adaptation or attenuation of cells
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2400/113: Acidophilus
- A23V 2400/123: Bulgaricus
- A23V 2400/125: Casei
- A23V 2400/151: Johnsonii
- A23V 2400/165: Paracasei
- A23V 2400/173: Reuteri
- A23V 2400/175: Rhamnosus
- A23V 2400/231: Lactis
- A23V 2400/249: Thermophilus
- A23V 2400/519: Breve
- A23V 2400/531: Lactis
- A23V 2400/533: Longum
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention generally relates to the field of preventing and/or treating inflammatory and infectious disorders, in particular by boosting the endogenous antimicrobial defenses. One embodiment of the present invention is the use of B. longum NCC2705 (deposit number CNCM 1-2618) for use in the treatment or prevention of disorders related to the immune system including infections.

## Claims

### Claim 1

A method for the treatment of infections and disorders related to the immune system, the method comprising administering a composition comprising B. longum NCC 2705 (deposit number CNCM I-2618) to an individual suffering from a disorder linked to a reduced level of defensins, wherein the disorder is selected from the group consisting of cystic fibrosis, reactive airways disease, lung infections from tobacco smoking, asthma, pneumonia, rhinitis, otitis, sinusitis, tuberculosis, ulcerative colitis, intestinal immaturity, necrotising enterocolitis, antibiotic-associated diarrhea, bacterial vaginosis, HIV, Herpes simplex virus, urinary infection, atopic dermatitis, carcinoma, atopic eczema, burn injury, tonsillitis, gingivitis, dental caries, keratitis in eyes, and combinations thereof, and at least 95% of the B. longum NCC 2705 (deposit number CNCM I-2618) are rendered non-replicating by a heat treatment.

### Claim 2 (depends on 1)

The method of claim 1, wherein the heat treatment is performed for at least 10 seconds.

### Claim 3 (depends on 1)

The method of claim 1, wherein the heat treatment is performed at a temperature ranging from about 110° to about 140° C. for an amount of time ranging from about 10 to about 20 seconds.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition comprises an amount of non-replicating B. longum NCC 2705 (deposit number CNCM I-2618) corresponding to about 104 to 1012 cfu per daily dose.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition comprises about 0.005 mg-1000 mg of non-replicating B. longum NCC 2705 (deposit number CNCM I-2618) per daily dose.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition is in a form selected from the group consisting of food compositions, pet foods, drinks, nutritional formulas, feeding formulas, nutraceuticals, food additives, pharmaceutical compositions, cosmetical compositions, topical compositions, medicaments, and combinations thereof.

### Claim 7

A method for boosting endogenous antimicrobial defenses, and/or the endogenous hBD2 and hBD1 expression, the method comprising administering a composition comprising B. longum NCC 2705 (deposit number CNCM I-2618) to an individual suffering from a disorder linked to a reduced level of defensins, wherein the disorder is selected from the group consisting of cystic fibrosis, reactive airways disease, lung infections from tobacco smoking, asthma, pneumonia, rhinitis, otitis, sinusitis, tuberculosis, ulcerative colitis, intestinal immaturity, necrotising enterocolitis, antibiotic-associated diarrhea, bacterial vaginosis, HIV, Herpes simplex virus, urinary infection, atopic dermatitis, carcinoma, atopic eczema, burn injury, tonsillitis, gingivitis, dental caries, keratitis in eyes, and combinations thereof, and at least 95% of the B. longum NCC 2705 (deposit number CNCM I-2618) are rendered non-replicating by a heat treatment.

### Claim 8 (depends on 1)

The method of claim 1, wherein the heat treatment is performed at a temperature ranging from 75° to 95° C. for an amount of time ranging from 10 to 30 minutes.

### Claim 9 (depends on 1)

The method of claim 1, wherein the heat treatment is performed at a temperature of about 120° C. for an amount of time of about 15 seconds.

### Claim 10 (depends on 1)

The method of claim 1, wherein the heat treatment is performed at a temperature of about 85° C. for an amount of time of about 20 minutes.

### Claim 11 (depends on 7)

The method of claim 7, wherein the heat treatment is performed at a temperature ranging from about 110° C. to about 140° C. for an amount of time ranging from about 10 to about 20 seconds.

### Claim 12 (depends on 7)

The method of claim 7, wherein the heat treatment is performed at a temperature ranging from 75° C. to 95° C. for an amount of time ranging from 10 to 30 minutes.

### Claim 13 (depends on 7)

The method of claim 7, wherein the heat treatment is performed at a temperature of about 120° C. for an amount of time of about 15 seconds.

### Claim 14 (depends on 7)

The method of claim 7, wherein the heat treatment is performed at a temperature of about 85° C. for an amount of time of about 20 minutes.